TCA
IKT icon

Transcend Capital Advisors’s Inhibikase Therapeutics IKT Stock Holding History

Transcend Capital Advisors’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92K Buy
45,298
+29,191
+181% +$52.2K 0.01% 802
2026
Q1 		$27.1K Buy
+16,107
New +$28.6K ﹤0.01% 716

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Transcend Capital Advisors's IKT Position: Q2 2026 in Review

Transcend Capital Advisors increased its Inhibikase Therapeutics (IKT) stake by 181% in Q2 2026, buying an estimated $52.2K and bringing the position to 45,298 shares worth $92K. The position accounts for 0.01% of the portfolio, ranked #802.

Transcend Capital Advisors first reported a position in IKT in Q1 2026 and has held it in 2 quarters since. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Transcend Capital Advisors held 45,298 shares of Inhibikase Therapeutics worth $92K as of Q2 2026.
  • Transcend Capital Advisors bought 29,191 Inhibikase Therapeutics shares in Q2 2026, an estimated $52.2K.
  • Inhibikase Therapeutics made up 0.01% of Transcend Capital Advisors's portfolio in Q2 2026, its #802 holding.
  • Transcend Capital Advisors first reported a position in Inhibikase Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.